Protagonist Therapeutics Total Assets Growth & History (PTGX)
Protagonist Therapeutics's total assets was $668.2M for fiscal 2025.
View full Protagonist Therapeutics company overviewProtagonist Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $668.2M | −$76.5M | −10.28% |
| 2024 | 2024-12-31 | $744.7M | $386.8M | +108.05% |
| 2023 | 2023-12-31 | $358.0M | $110.0M | +44.38% |
| 2022 | 2022-12-31 | $247.9M | −$99.8M | −28.69% |
| 2021 | 2021-12-31 | $347.7M | $23.2M | +7.16% |
| 2020 | 2020-12-31 | $324.5M | $169.6M | +109.45% |
| 2019 | 2019-12-31 | $154.9M | $15.4M | +11.07% |
| 2018 | 2018-12-31 | $139.5M | −$24.3M | −14.82% |
| 2017 | 2017-12-31 | $163.7M | $69.7M | +74.20% |
| 2016 | 2016-12-31 | $94.0M | $79.1M | +533.14% |
| 2015 | 2015-12-31 | $14.8M | — | — |
Protagonist Therapeutics quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $885.5M | $167.5M | +23.33% |
| Q1 2026 | 2026-03-31 | $697.5M | −$44.7M | −6.02% |
| Q4 2025 | 2025-12-31 | $668.2M | −$76.5M | −10.28% |
| Q3 2025 | 2025-09-30 | $701.7M | $97.8M | +16.20% |
| Q2 2025 | 2025-06-30 | $718.0M | $103.4M | +16.82% |
| Q1 2025 | 2025-03-31 | $742.1M | $112.9M | +17.93% |
| Q4 2024 | 2024-12-31 | $744.7M | $386.8M | +108.05% |
| Q3 2024 | 2024-09-30 | $603.9M | $273.8M | +82.98% |
| Q2 2024 | 2024-06-30 | $614.6M | $294.2M | +91.79% |
| Q1 2024 | 2024-03-31 | $629.3M | $389.4M | +162.35% |
| Q4 2023 | 2023-12-31 | $358.0M | $110.0M | +44.38% |
| Q3 2023 | 2023-09-30 | $330.0M | $47.8M | +16.95% |
| Q2 2023 | 2023-06-30 | $320.5M | $10.0M | +3.21% |
| Q1 2023 | 2023-03-31 | $239.9M | −$108.4M | −31.13% |
| Q4 2022 | 2022-12-31 | $247.9M | −$99.8M | −28.69% |
| Q3 2022 | 2022-09-30 | $282.2M | −$91.0M | −24.39% |
| Q2 2022 | 2022-06-30 | $310.5M | −$93.7M | −23.18% |
| Q1 2022 | 2022-03-31 | $348.3M | $50.2M | +16.85% |
| Q4 2021 | 2021-12-31 | $347.7M | $23.2M | +7.16% |
| Q3 2021 | 2021-09-30 | $373.2M | $155.9M | +71.72% |
| Q2 2021 | 2021-06-30 | $404.2M | $179.3M | +79.67% |
| Q1 2021 | 2021-03-31 | $298.1M | $163.2M | +120.96% |
| Q4 2020 | 2020-12-31 | $324.5M | $169.6M | +109.45% |
| Q3 2020 | 2020-09-30 | $217.3M | $62.7M | +40.54% |
| Q2 2020 | 2020-06-30 | $225.0M | $76.9M | +51.91% |
| Q1 2020 | 2020-03-31 | $134.9M | $2.7M | +2.01% |
| Q4 2019 | 2019-12-31 | $154.9M | $15.4M | +11.07% |
| Q3 2019 | 2019-09-30 | $154.6M | $5.8M | +3.88% |
| Q2 2019 | 2019-06-30 | $148.1M | $10.6M | +7.73% |
| Q1 2019 | 2019-03-31 | $132.2M | −$17.0M | −11.39% |
| Q4 2018 | 2018-12-31 | $139.5M | −$24.3M | −14.82% |
| Q3 2018 | 2018-09-30 | $148.9M | $38.4M | +34.82% |
| Q2 2018 | 2018-06-30 | $137.5M | $67.0M | +95.06% |
| Q1 2018 | 2018-03-31 | $149.2M | $66.6M | +80.52% |
| Q4 2017 | 2017-12-31 | $163.7M | $69.7M | +74.20% |
| Q3 2017 | 2017-09-30 | $110.4M | $7.6M | +7.36% |
| Q2 2017 | 2017-06-30 | $70.5M | $46.0M | +187.48% |
| Q1 2017 | 2017-03-31 | $82.7M | — | — |
| Q4 2016 | 2016-12-31 | $94.0M | $79.1M | +533.14% |
| Q3 2016 | 2016-09-30 | $102.8M | — | — |
| Q2 2016 | 2016-06-30 | $24.5M | — | — |
| Q4 2015 | 2015-12-31 | $14.8M | — | — |
Protagonist Therapeutics total assets trends
Over the last five fiscal years, Protagonist Therapeutics's total assets increased from $324.5M to $668.2M, a change of $343.7M. The latest reported quarter, Q2 2026, shows $885.5M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagonist Therapeutics source filings ↗